Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.incyte.com
Incyte Corporation News Releases
Get the latest updates from Incyte Corporation News Releases directly as they happen.
Follow now 164 followers
Latest posts
Last updated 2 days ago
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--May 7, 2025-- Incyte (Nasdaq:INCY) today announced that it...
Incyte to Present at Upcoming Investor Conference
9 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--May 1, 2025-- Incyte (Nasdaq:INCY) announced today that it...
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
11 days ago
– Total revenues of $1,053 million in the first quarter (Q1'25) (+20%...
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
15 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 25, 2025-- Incyte (Nasdaq:INCY) today announced that the...
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
16 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 23, 2025-- Incyte (Nasdaq: INCY) today announced that...
Incyte to Report First Quarter Financial Results
30 days ago
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 10, 2025-- Incyte (Nasdaq: INCY) announced today that...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 1 month ago
WILMINGTON, Del. --(BUSINESS WIRE)--Apr. 7, 2025-- Incyte (Nasdaq:INCY) today announced that it...
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
about 2 months ago
- Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2...
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
2 months ago
- Full data from the Phase 3 TRuE-PN1 study, presented today in...
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago
WILMINGTON, Del. --(BUSINESS WIRE)--Mar. 7, 2025-- Incyte (Nasdaq:INCY) today announced that it...
Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting
2 months ago
- Featured abstracts for ruxolitinib cream (Opzelura ® ) include multiple presentations...
Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration
3 months ago
Incyte and Genesis will leverage Genesis’ GEMS artificial intelligence (AI) platform to...